Shares of Emergent Biosolutions Inc (NYSE:EBS) have earned an average rating of “Buy” from the six analysts that are covering the company. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating on the company. The average 1 year target price among brokers that have covered the stock in the last year is $41.00.

Several equities analysts have recently commented on EBS shares. Chardan Capital restated a “buy” rating and set a $47.00 price target on shares of Emergent Biosolutions in a research report on Monday, January 30th. Zacks Investment Research lowered shares of Emergent Biosolutions from a “hold” rating to a “sell” rating in a research report on Wednesday, February 8th.

COPYRIGHT VIOLATION NOTICE: This news story was first published by American Banking News and is the property of of American Banking News. If you are reading this news story on another website, it was illegally stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/05/16/emergent-biosolutions-inc-ebs-receives-consensus-rating-of-buy-from-analysts.html.

In related news, EVP Adam Havey sold 11,419 shares of the stock in a transaction dated Monday, April 3rd. The shares were sold at an average price of $28.62, for a total value of $326,811.78. Following the completion of the transaction, the executive vice president now owns 26,046 shares in the company, valued at approximately $745,436.52. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Jerome M. Hauer sold 2,576 shares of the stock in a transaction dated Wednesday, March 8th. The shares were sold at an average price of $31.27, for a total transaction of $80,551.52. Following the completion of the transaction, the director now owns 17,404 shares of the company’s stock, valued at approximately $544,223.08. The disclosure for this sale can be found here. 17.20% of the stock is currently owned by corporate insiders.

A number of institutional investors have recently made changes to their positions in the stock. New Amsterdam Partners LLC NY raised its position in shares of Emergent Biosolutions by 34.7% in the third quarter. New Amsterdam Partners LLC NY now owns 145,797 shares of the biopharmaceutical company’s stock worth $4,597,000 after buying an additional 37,535 shares in the last quarter. BlackRock Investment Management LLC raised its position in shares of Emergent Biosolutions by 1.1% in the third quarter. BlackRock Investment Management LLC now owns 136,722 shares of the biopharmaceutical company’s stock worth $4,311,000 after buying an additional 1,462 shares in the last quarter. New York State Common Retirement Fund raised its position in shares of Emergent Biosolutions by 48.2% in the third quarter. New York State Common Retirement Fund now owns 109,712 shares of the biopharmaceutical company’s stock worth $3,459,000 after buying an additional 35,707 shares in the last quarter. Rhumbline Advisers raised its position in shares of Emergent Biosolutions by 9.8% in the third quarter. Rhumbline Advisers now owns 46,455 shares of the biopharmaceutical company’s stock worth $1,465,000 after buying an additional 4,163 shares in the last quarter. Finally, BlackRock Group LTD raised its position in shares of Emergent Biosolutions by 6.0% in the third quarter. BlackRock Group LTD now owns 68,092 shares of the biopharmaceutical company’s stock worth $2,147,000 after buying an additional 3,824 shares in the last quarter. Hedge funds and other institutional investors own 89.61% of the company’s stock.

Emergent Biosolutions (NYSE:EBS) opened at 31.53 on Tuesday. Emergent Biosolutions has a 12 month low of $24.47 and a 12 month high of $44.38. The firm’s 50-day moving average is $29.46 and its 200 day moving average is $30.07. The stock has a market capitalization of $1.29 billion, a P/E ratio of 25.06 and a beta of 1.02.

Emergent Biosolutions (NYSE:EBS) last released its quarterly earnings results on Thursday, May 4th. The biopharmaceutical company reported $0.23 EPS for the quarter, missing the consensus estimate of $0.31 by $0.08. The firm had revenue of $116.90 million for the quarter, compared to the consensus estimate of $121.30 million. Emergent Biosolutions had a return on equity of 10.42% and a net margin of 9.12%. The firm’s revenue was up 13.5% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.16 EPS. On average, equities analysts anticipate that Emergent Biosolutions will post $1.58 earnings per share for the current year.

About Emergent Biosolutions

Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).

5 Day Chart for NYSE:EBS

Receive News & Ratings for Emergent Biosolutions Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions Inc and related companies with MarketBeat.com's FREE daily email newsletter.